FDA Approved: KANJINTI — Original Application (Amgen, Inc)

View source ↗

Summary

FDA approves KANJINTI (trastuzumab-anns) from Amgen as a biosimilar to trastuzumab. It is approved for HER2-overexpressing breast cancer and HER2-positive gastr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• KANJINTI (TRASTUZUMAB-ANNS)

Snippet

ORIG AP for KANJINTI (TRASTUZUMAB-ANNS)